TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00902811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM(FDC)
Description: Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AM(LT)
Description: Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL
Description: Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP
Description: 40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group \<6yrs of age, a subdivision according to weight is made

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AA(FDC)
Description: Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
Study: NCT00098397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT03714568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3326
Description: TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
Study: NCT04733625

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo medication
Study: NCT00802672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine Cream
Description: topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loprox Cream 0.77%
Description: topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical cream
Study: NCT01254084

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gynostemma Pentaphyllum tea
Description: 6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
Study: NCT04214353

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-PET/CT
Description: All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18FDG-PET/CT
Description: All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
Study: NCT01254084

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: 6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
Study: NCT04540237

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-cytometric analysis
Description: Flow-cytometric analysis of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-cytometric analysis
Description: Flow-cytometric analysis of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33
Study: NCT01228175

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25mg look alike riboflavin tablets to match active study medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
Study: NCT01377246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Description: 40 mg every 28 days (in two intragluteal 20 mg injections) for three years

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution.
Description: At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
Study: NCT01111110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static then anti-static chamber
Description: albuterol with Static then anti-static chambers
Study: NCT01663038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel and Aspirin separate combination, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination of clopidogrel/Aspirin
Description: Fixed dose combination of clopidogrel/aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT05102058

Intervention type: DRUG
Intervention: Magnesium-Dexmedetomidine
Description: Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively
Study: NCT02903017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid 5%
Description: Via nasogastric tube, 100 mL
Study: NCT04195295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration of Intrabony Defects with Nano Hydroxyapatite Graft, Derived from Egg Shell along with Periosteum as Barrier Membrane
Description: * In group A, the full thickness mucoperiosteal flap will be elevated, which will be extended apically to expose sufficient amount of periosteum.~* Periosteal membrane will be separated from the full thickness mucoperiosteal flap and released by one vertical incision mesially and one horizontal incision apically.~* Posteriorly, the periosteum remained attached with the mucoperiosteal flap, so that blood supply could be maintained in the reflected periosteum.~* Then the graft material will be packed into the defect.~* Then periosteal membrane will be turned over the intrabony defect in such a way that the defect was completely covered by the periosteal membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration of intrabony defects using Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material
Description: Full thickness mucoperiosteal flap will be raised and Vertical releasing incisions are used if necessary for better access to the surgical site. Then EnHA graft material will be placed into the defect before suturing the mucoperiosteal flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement procedure in intrabony defects.
Description: full thickness mucoperiosteal flap will be raised, entire granulation tissue will be removed from the defects, the pocket epithelium was curetted from the inner surface of the flap, and the roots were thoroughly scaled and planed by means of manual and ultrasonic instruments. Then the operative area will be irrigated with sterile saline. After that, the mucoperiosteal flaps will be sutured.
Study: NCT01024738

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush half mouth twice daily for four days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, fluoride
Description: Brush twice daily
Study: NCT01375452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
Study: NCT01797588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor-canal block
Description: The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor-canal block
Description: The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular infiltration
Description: Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular infiltration
Description: Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.
Study: NCT02965508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Primary Care
Description: Care in the programs is inter-professional and team-based. Each physician leads a team charged with the care of a panel of patients and directs the team's activities. New patients are assigned a Mount Sinai Visiting Doctors (MSVD) primary care physician or the Chelsea Village House Calls Program (CVHCP) who makes an initial visit within 2 weeks of the patient's enrollment in the program. The primary care physician completes a comprehensive medical history and physical exam during the initial visit including standardized assessments of physical functioning and cognition. The primary care physician then provides ongoing management of the patients' acute and chronic health problems, including palliative and home hospice care when needed, every 2 to 12 weeks as determined on a case-by-case basis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Office based care
Study: NCT01269099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-PCA
Description: IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: control group (No-PCA group)
Study: NCT02301819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Veno-arterial extracorporeal membrane oxygenation (ECMO)
Description: Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early conservative therapy according to standard practice
Description: Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
Study: NCT02903017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Via nasogastric tube, 100 mL
Study: NCT00984191

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI SPECT-CT
Description: 99mTc-MIBI SPECT-CT for abnormal cervical lymph node

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI SPECT-CT
Description: 99mTc-MIBI SPECT-CT for abnormal cervical lymph node
Study: NCT03769701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: self-monitoring capillary glucose (SMCG)
Description: To measure the capillary glucose with a glucometer according to the assigned group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: self-monitoring capillary glucose (SMCG)
Description: To measure the capillary glucose with a glucometer according to the assigned group.
Study: NCT00984191

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI SPECT-CT
Description: 99mTc-MIBI SPECT-CT for abnormal cervical lymph node
Study: NCT02332902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
Study: NCT00855855

Intervention type: BIOLOGICAL
Intervention: DTaP-IPV/Hib
Description: 0.5 mL, Intramuscular
Study: NCT03998449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination against cholera
Description: Participants will receive two doses of an oral cholera vaccine with an interval of 2-4 weeks.
Study: NCT02400775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan tablets
Study: NCT01862068

Intervention type: OTHER
Intervention: Blood samples and clinical data
Description: Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)

Intervention type: OTHER
Intervention: Blood samples and clinical data
Description: Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)

Intervention type: OTHER
Intervention: Blood samples and clinical data
Description: Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)

Intervention type: OTHER
Intervention: Blood samples and clinical data
Description: Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample will be performed at inclusion from all healthy patients
Study: NCT03530137

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Home
Description: An evidence-based health literacy curriculum will be developed and implemented based on competencies of understanding and applying health information. The

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attachment and Biobehavioral Catch-up Infant (6-24 months) and Toddler (24-48 months).
Description: ABC includes 10 in-home, manualized sessions with parents and infants, targeting: 1) increasing parents' nurturing when children are distressed, 2) helping parents follow children's lead, 3) decreasing frightening parent behaviors, and (for ABC-Toddler) managing dysregulation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HealthySteps
Description: Healthy Steps helps families identify, understand and manage parenting challenges like feeding, behavior, sleep, development and adjusting to life with a young child
Study: NCT03041792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01568125

Intervention type: DRUG
Intervention: Incretin-related drugs
Description: DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
Study: NCT00839956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT03656250

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT scans
Description: (approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
Study: NCT02091115

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dairy drink with probiotic culture
Description: The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dairy drink
Study: NCT00661297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10 mg Vardenafil to be taken 1 h prior to sexual attempt

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00373451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab + UFH
Description: Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute \[maximum of 10 µg/minute\] infusion for 12 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: i.v. bolus of 70 units/kg/body weight of unfractionated heparin
Study: NCT00003485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antineoplaston A10, antineoplaston AS2-1 (ANP)
Description: Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT03573193

Intervention type: OTHER
Group type: OTHER
Intervention: ridge preservation
Description: Intra operative procedures (for both groups) ridge preservation~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~* In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~* In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ridge preservation
Description: Intra operative procedures (for both groups) ridge preservation~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~* In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~* In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP).
Study: NCT04134624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sepsis care bundle
Description: Initiation of sepsis care bundle in prehospital setting, including collection of blood cultures, administration of antibiotics, and initiation of IV fluids
Study: NCT02834299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT Guided Self-Help
Description: DBT self-help manual plus six 30-minute therapy sessions for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT Unguided Self-Help
Description: DBT self-help manual without any therapy sessions for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Esteem-Focused Unguided Self-Help
Description: Self-esteem focused self-help manual without any therapy sessions for 12 weeks
Study: NCT02809560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induced sputum method using hypertonic serum
Description: Collection of expectoration in sterile vial, conserved in ice all along the examination

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Induced sputum method using hypertonic serum
Description: Collection of expectoration in sterile vial, conserved in ice all along the examination
Study: NCT00006462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT01607476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11 PiB
Description: One time intravenous administration of 8-22 millicurie (mCi) C11 PiB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C11 PiB
Description: One time intravenous administration of 8-22 millicurie (mCi) C11 PiB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C11 PiB
Description: One time intravenous administration of 8-22 millicurie (mCi) C11 PiB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18 Flutametamol
Description: One time intravenous administration of 3-7 mCi F18 Flutametamol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F18 Flutametamol
Description: One time intravenous administration of 3-7 mCi F18 Flutametamol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F18 Flutametamol
Description: One time intravenous administration of 3-7 mCi F18 Flutametamol.
Study: NCT01024738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Rinse mouth twice a day
Study: NCT04076501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen application
Description: Oxygen application Supplemental oxygen via mask

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham room air
Description: Room air applied via mask
Study: NCT03408366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparotomy
Description: Laparotomy via vertical midline incision and after the planned surgical procedure is complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG
Description: ICG will be injected intravenously ICG is a fluorescent iodide dye.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spectrum NIR imaging system
Description: The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
Study: NCT03806036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 300.000 I.U single dose of VIT D IM injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene Citrate
Description: 100mg daily for 5 days starting from third day of menstruation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: 100mg daily for 5 days starting from third day of menstruation
Study: NCT00670956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: 12 mg intramuscularly x 2 doses 24 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLACEBO: IM x 2 doses 24 hours apart